Yen Tzu-Chen, Lin Chien-Yu, Wang Hung-Ming, Huang Shiang-Fu, Liao Chun-Ta, Kang Chung-Jan, Ng Shu-Hang, Chan Sheng-Chieh, Fan Kang-Hsing, Chen I-How, Lin Wuu-Jyh, Cheng Ann-Joy, Chang Joseph Tung-Chieh
Molecular Imaging Center, Taipei Chang Gung Head and Neck Oncology Group, Chang Gung Memorial Hospital-Linkou Medical Center, Chang Gung University, Taoyuan, Taiwan.
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1307-14. doi: 10.1016/j.ijrobp.2006.02.031.
This article evaluates [18F] fluorodeoxyglucose positron emission tomography (18F-FDG-PET) findings as a predictor for local responders (R) vs. nonresponders (NR) in nasopharyngeal carcinoma (NPC) patients with Stage T4 lesions, before and at 3 months after completion of concurrent chemotherapy and radiation therapy (CCRT).
From January 2002 to November 2003, 39 T4 NPC patients were enrolled. All had magnetic resonance imaging and 18F-FDG-PET, both before and 3 months after CCRT. Any residual/recurrent lesions were confirmed histopathologically.
Of the 39 eligible patients, after a follow-up of 24.2 +/- 9.5 months, 35 became disease-free and 4 had residual or recurrent disease. Marginal differences in standard uptake values (SUV) were observed (10.9 +/- 5.3 vs. 15.6 +/- 3.4, p = 0.058) between R and NR before treatment, and value changes of SUV before and after CCRT were not significantly different. However, highly significantly lower values of SUV were noted for R than for NR 3 months after completion of CCRT (2.1 +/- 0.8 vs. 5.5 +/- 3.2, p = 0.001). One hundred percent positive and negative predictive values were observed for SUV values of 4.0, set 3 months after completion of CCRT.
Neither the pretreatment SUV nor the changes of SUV between pretreatment and posttreatment were significant predictors for local response. SUV at 3 months after completion of CCRT was a significant determinator for local response. The cutoff of 4.0 for SUV at 3 months after completion of CCRT was useful to be offered as a diagnostic reference for recurrent or residual tumor for NPC treatment.
本文评估[18F]氟脱氧葡萄糖正电子发射断层扫描(18F-FDG-PET)检查结果,以预测T4期鼻咽癌(NPC)患者在同步放化疗(CCRT)完成前及完成后3个月时局部缓解者(R)与未缓解者(NR)的情况。
2002年1月至2003年11月,纳入39例T4期NPC患者。所有患者在CCRT前及CCRT后3个月均接受了磁共振成像和18F-FDG-PET检查。任何残留/复发病变均经组织病理学证实。
39例符合条件的患者,经过24.2±9.5个月的随访,35例无病生存,4例有残留或复发病变。治疗前R组和NR组的标准摄取值(SUV)存在边际差异(10.9±5.3 vs. 15.6±3.4,p = 0.058),CCRT前后SUV的变化无显著差异。然而,CCRT完成后3个月,R组的SUV值显著低于NR组(2.1±0.8 vs. 5.5±3.2,p = 0.001)。CCRT完成后3个月设定的SUV值为4.0时,观察到100%的阳性和阴性预测值。
治疗前SUV及治疗前后SUV的变化均不是局部缓解的显著预测指标。CCRT完成后3个月的SUV是局部缓解的显著决定因素。CCRT完成后3个月SUV的临界值4.0可作为NPC治疗中复发或残留肿瘤的诊断参考。